Rho Chi Post

An award-winning, electronic, student-operated newsletter publication by the St. John's University College of Pharmacy and Health Sciences Rho Chi Beta Delta chapter

Menu

Skip to content
  • Home
  • Issues
    • Current Issue
    • All Issues
  • Articles
    • Featured
    • In the News / Politics
    • Events
    • Clinical
    • Advice / Opinions
    • Puzzles
    • Recently in PubMed
  • For Authors
    • Author Guidelines
    • AMA Citation Generator
    • Sign Up for Article(s)
    • Suggest Article(s)
    • Submit Article(s)
    • Check Statuses
    • Cite Your Article
  • About Us
    • About the Rho Chi Post
    • The Editorial Team
  • Apply for a Position
  • Subscribe
  • Login

Clinical

Newly Approved: Macitentan (Opsumit®)...
December 1, 2013 - Clinical , Featured

By: Rebecca Gilene, PharmD Candidate c/o 2014, St. Louis College of Pharmacy – The FDA approved macitentan (Opsumit®) on October 18, 2013 for the treatment of pulmonary arterial hypertension.1 Pulmonary arterial hypertension, often referred to as PAH, is a disease characterized by high blood pressure in the arteries between the heart and lungs. An increase…

Zecuity(TM): Novel Treatment Option for Migraines...
November 1, 2013 - Clinical

By: Arya Mathew, PharmD Candidate c/o 2014 –  About twelve percent of the U.S. population suffers from migraines, affecting adult women three times more than adult men.  Migraines are returning attacks of moderate to severe, throbbing or pulsing pain, usually on one side of the head.  Along with the severe pain, migraine sufferers also experience…

Ceftriaxone Induced Hemolytic Anemia...
November 1, 2013 - Clinical , Featured

By: Samad Tirmizi, PharmD Candidate c/o 2014 – Hemolytic anemia (HA) is a type of anemia that occurs due to the breakdown of red blood cells. It is classified as intrinsic and extrinsic according to causative factors. Medication induced hemolytic anemia is an example of extrinsic, while genetic predisposition is an intrinsic factor. Drug induced…

Does Moxifloxacin Increase the Risk of Dysglycemia?...
November 1, 2013 - Clinical , Featured

By: Nathan Trustman, PharmD Candidate c/o 2014, AMSCOP at LIU – The antibiotic class known as the fluoroquinolones is widely used in both outpatient and inpatient settings. They provide bactericidal effects by inhibiting DNA gyrase and topoisomerase IV enzymes in bacteria. The systemic agents that are most commonly used in clinical practice include ciprofloxacin, levofloxacin,…

New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical

By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who…

New Drug to Treat HIV-1 Hits the Market...
October 1, 2013 - Clinical , Featured

By: Ada Seldin, Staff Editor – On August 12,2013, a new weapon against HIV-1 infection was added to the existing armada. Dolutegravir, the third integrase strand transfer inhibitor to attain FDA approval, targets a protein essential to HIV replication. HIV-1 is the predominant type of HIV virus, the other being HIV-2, which is endogenous to…

After 15 Years, First New Recombinant Coagulation Facto...
October 1, 2013 - Clinical

By: Tamara Yunusova, Senior Staff Editor – After a lengthy fifteen-year hiatus in recombinant drug approvals, FDA-approved Recombinant Coagulation Factor IX (Rixubis) has mounted to the forefront of Hemophilia B drug therapy. The recombinant coagulation factor gained orphan drug approval on June 26, 2013 for routine prophylaxis, control of bleeding episodes, and perioperative management in…

Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical

By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily…

Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical

Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are…

Children, Codeine, and Cytochrome P-450...
September 1, 2013 - Clinical , Featured

By Davidta Brown, Staff Editor – For post-operative pain treatment, few drugs are as trustworthy, as tried-and-true, as codeine. Prescriptive confidence in the analgesic has promoted its use in children recovering from uncomplicated surgeries, but the spate of injuries and deaths of young children who had been given codeine after undergoing adenotonsillectomies has provoked a…

A Close Concurrence on Certolizumab (Cimzia®)...
September 1, 2013 - Clinical , Featured

By: Sang Hyo Kim, Staff Editor – This year, on July 23rd, FDA advisers voted 7 to 6, with one abstention, in favor of approving the drug certolizumab (Cimzia®) for the indication of axial spondyloarthritis (axSpA). axSpA is a chronic imflammatory condition that includes ankylosing spondylitis (AS) and non-radiographic axial spndyloarthristis (nr-axSpA).1,2 axSpA, AS and…

New Findings Regarding Cardiovascular Adverse Events wi...
August 1, 2013 - Clinical , Featured

By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve…

Comparison of the New Oral Antithrombotics and Warfarin...
August 1, 2013 - Clinical , Featured

By Omar Khalid Pharm.D. Candidate c/o 2014 – The outpour of a multitude of new oral anticoagulants in recent years has health care professionals questioning whether they should switch the patients over, and what new agents should be used. With the recent addition of dabigatran (Pradaxa®) in October 2010, rivaroxaban (Xarelto®) in November 2011, and…

Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured

By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated…

Understanding Opioid Overdose...
July 1, 2013 - Clinical , Featured

By: Aleena Cherian, PharmD Candidate c/o 2014 – Although opioid analgesics are among the most effective drugs to treat pain, they are associated with a growing number of public health issues including addiction and severe, often fatal, overdoses. The recent increase in incidences of opioid overdose is directly correlated to rapidly increasing and widespread use…

Solving the HCV Enigma: Current and Future Drug Therapy...
July 1, 2013 - Clinical , Featured

By: Tamara Yunusova, Senior Staff Editor – Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are not common, rates of chronic hepatitis C continue to surge due to the recent discovery of the virus in 1989 and consequently, the establishment of a test screening for HCV antibodies in 1992.1 HCV has…

FDA Approves Dimethyl Fumarate for Treatment of Relapsi...
June 1, 2013 - Clinical , Featured

By: Andy Zhang, PharmD Candidate c/o 2015 – On March 28, 2013, the U.S. Food and Drug Administration announced the approval of Tecfidera™ (dimethyl fumarate) for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 Tecfidera™ (dimethyl fumarate) will be the third oral drug used for the treatment of MS. The manufacturer Biogen…

Noninvasive Cancer Screening—Will We Ever Get It Righ...
June 1, 2013 - Clinical , Featured

By: Frances Sousonis, Candidate c/o 2017 – Unfortunately, cancer is a disease about which many are able to share stories. All too often, beloved persons are diagnosed with cancer, or, more regrettably, loses their battle with the beast. Colon cancer is the third most common cancer in the United States and around 150,000 people each…

Can a Pharmacist Prevent the Next Pileup?...
May 1, 2013 - Clinical

By: Moisey Rafailov, PharmD Candidate c/o 2015 – It was early in the morning on New York’s Route 684 when a car hit a tractor-trailer and continued driving without regard. Imagine that, when later stopped by a police officer, the driver said that the accident was her pharmacist’s fault. What if I were to tell…

Purple Glove Syndrome...
May 1, 2013 - Clinical , Featured

By: Sharon Janak, PharmD Candidate c/o 2013 – How can we distinguish between vascular injury and Purple Glove Syndrome (an adverse effect of phenytoin)?  What are the warning signs and symptoms? Phenytoin is an anticonvulsant used to treat generalized tonic-clonic and partial seizures. It stabilizes neuronal cell membranes of the motor cortex by facilitating the…

Alzheimer’s Disease On The Rise...
May 1, 2013 - Clinical , Featured

By: Ada Seldin – An impending storm is threatening to stagger the health care system and the nation at large. Alzheimer’s disease, which now affects as many as 5.1 million Americans, is projected to triple its toll by 2050, to 13.8 million Americans.1 These sky-rocketing rates can be attributed to aging of the ‘baby boomers.’2…

FDA Approves New Drug ‘Tofacitinib’ for Rheumatoid ...
April 1, 2013 - Clinical , Featured

By: Erica Dimitropoulos, Senior Staff Editor – Rheumatoid arthritis is a painful and often debilitating autoimmune disease characterized by symmetric polyarthritis, most commonly of the proximal interphalangeal and metacarpophalangeal joints, elbows, knees, ankles, and spine.1 Its clinical manifestations vary, from a slowly progressing onset of fatigue and musculoskeletal discomfort to a sudden and worsening destruction…

Say Goodbye to Yearly Flu Shots—The Universal Flu Vac...
April 1, 2013 - Clinical , Featured

By: Diana Gritsenko, Pharm D. Candidate c/o 2015 – Every flu season, it is the same story: long lines at doctors’ offices and pharmacy counters as patients scramble to get the year’s vaccine before supplies run out. Year after year, doctors and pharmacists groan while explaining over and over again to patients why they need…

Flu Season 2012-2013: Rising Opportunities for Pharmaci...
April 1, 2013 - Clinical

By: Fawad Piracha, Pharm. D Candidate c/o 2016 – The 2012-2013 influenza season has developed into one of the greatest nationwide flu outbreaksof the decade.1 Amid this crisis, many flocked to healthcare providers with flu-like symptoms, while others scoured doctors’ offices, clinics, and pharmacies for the vaccine. With the flu claiming many lives throughout the…

Documentation of Drug Allergies in Hospitalized Older A...
April 1, 2013 - Clinical , Featured

By: Nandini Puranprashad, PharmD Candidate; Sibyl Cherian, PharmD Candidate; Tracey Cannova, PharmD Candidate; and Olga HilasPharmD, MPH, BCPS, CGP  – Adverse drug reactions are estimated to occur in 10-20% of hospitalized patients and in 7% of the general population.1 One-third of these reactions are of an allergic or pseudo-allergic nature. The consequences of these hypersensitivity…

New P2Y12 Antagonist on the Rise...
April 1, 2013 - Clinical

By Nancy Rizkalla, PharmD candidate c/o 2015 –        Percutaneous coronary intervention (PCI) with subsequent stent implantation is a highly effective approach in reducing the risk of death or ischemic complications following a myocardial infarction as well as improving the quality of life in patients with stable angina. PCI is ultimately performed in 60 –…

New FDA Approval: Fycompa® to Treat Seizures...
March 1, 2013 - Clinical , Featured

By: Bhavini Shah, PharmD Candidate c/o 2013  – Fycompa® (perampanel) has received the U.S. Food and Drug Administration (FDA) approval for the adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.1  The drug, manufactured by Eisai Inc., is already approved for use in Iceland,…

FDA Approves New Indication for Botox (Onabotulinumtoxi...
March 1, 2013 - Clinical , Featured

By: Bethsy Jacob, PharmD Candidate 2014 – On January 18, 2013, the U.S. Food and Drug Administration (FDA) announced a new approval for Botox, generically known as OnabotulinumtoxinA. Patients diagnosed with urinary incontinence due to an overactive bladder can be prescribed Botox, if they are unable to take or are unresponsive to anticholinergic medications.  This…

Calcium Intake and Risk of Myocardial Infarction...
February 1, 2013 - Clinical , Featured

By:  Lila Ahmed, PharmD Candidate c/o 2013 – In the past, numerous research efforts have attempted to prove the benefits and risks of calcium and multivitamin supplements with little success. Most of the studies performed were inconclusive and did not provide us with significant data; while some studies have found that calcium is beneficial for…

Liraglutide (Victoza®) for Type 2 Diabetes Mellitus...
February 1, 2013 - Clinical , Featured

By:  Miriam Maltz, PharmD Candidate c/o 2013, AMSCOP, Long Island University – Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by hyperglycemia that is pursuant to insulin resistance, defects in insulin secretion, or both1. Chronic hyperglycemia is associated with detrimental effects on various organ systems that can increase mortality and impact the patient’s…

Emerging Pathways For Treating Hepatitis C Virus...
February 1, 2013 - Clinical , Featured

By:  Maria Sorbera, PharmD Candidate c/o 2013, AMSCOP, LIU – Hepatitis C is the leading cause of chronic liver disease and cirrhosis, presenting a global health challenge.  Approximately 170 million people worldwide, 3% of the population, are infected with the Hepatitis C Virus (HCV), roughly 3.2 million of whom reside in the United States.  The…

FDA Approves Apixaban For Nonvalvular Atrial Fibrillati...
January 1, 2013 - Clinical , Featured , In the News / Politics

By: Alexandra Alleva, PharmD candidate c/o 2013 – As of December 28th, Bristol-Myers Squibb and Pfizer’s brand name oral anticoagulant, Eliquis® (apixaban), attained FDA approval.1  This occurred one month after its approval in  Europe and Canada, following longer than expected waits in the US due to further investigation requests by the FDA.2 The much-anticipated anticoagulant is…

Breakthroughs in Gene Therapy: Pharmacogenetics and Vec...
December 1, 2012 - Clinical , Featured

By: Tamara Yunusova, PharmD Candidate c/o 2017 – Gene therapy? You scoff in disbelief as thoughts of designer babies, liberal eugenics, clones, and ruthless dystopian societies begin to reel in the back of your mind. Perhaps you may even stop to recall a scene or two from Jurassic Park or Star Trek. Undoubtedly, gene therapy…

Are You Prepared for RSV Season?...
November 1, 2012 - Clinical , In the News / Politics

By: Mahdieh Danesh Yazdi, Associate Student Editor – Many of us have prepared for influenza season by receiving the flu vaccine.  (If you have not, please speak to your doctor or pharmacist soon!  Remember: even if you do not need it for your protection, get it for your patients’ well-being).  However, for the youngest members…

Safety and Efficacy of Atropine for Salivary Hypersecre...
November 1, 2012 - Clinical

By: Elsa Thomas, PharmD Candidate c/o 2013 – Atropine is an anticholinergic used to treat various conditions, such as bradycardia, neuromuscular blockade, mydriasis, nerve agent poisoning, and salivary hypersecretion.1,2  Pharmacologically, it inhibits smooth muscle and glands innervated by postganglionic cholinergic nerves.1,2  It also has functions in the central nervous system (CNS); it could stimulate or…

New Drug Review: Tofacitinib (Xeljanz®)...
November 1, 2012 - Clinical

By: Jessica Lee, PharmD Candidate c/o 2013 – Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks healthy tissue, causing inflammation of the joints and potential harm to other organs.1  It affects 0.5-1% of the adult population and is more prevalent in the seventh decade of life.1  These patients tend to…

Mechanisms of NSAID Induced Functional Renal Toxicity...
November 1, 2012 - Clinical , Featured

By: James W.  Schurr & Stephen Argiro, PharmD Candidates c/o 2014 – Patients frequently utilize non-steroidal anti-inflammatory drugs (NSAIDs) for a wide variety of conditions, including but not limited to arthritis, headaches, and generalized pain.  Despite an excellent safety profile, NSAIDs are associated with certain toxicities, including renal complications (particularly among at risk populations).1  Acute…

SSRI Discontinuation Syndrome...
November 1, 2012 - Clinical

By: Shannon Tellier, PharmD Candidate c/o 2013 – Antidepressant discontinuation syndrome has been reported in all categories of antidepressants after an abrupt interruption of therapy.1  Symptoms usually occur within a few days of stopping or reducing the dosage of the antidepressant, and rarely occur with therapy of less than five weeks.1  If left untreated, most…

Ivacaftor (KalydecoTM): Targeting the Core of Cystic Fi...
November 1, 2012 - Clinical , Featured

By: Eugene Kolomiyets, PharmD Candidate c/o 2013, AMSCOP at LIU – Cystic fibrosis (CF) is an autosomal recessive disease caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7.1  The disease has been linked to thousands of possible mutations, but only as many as 25-30 are tested for…

Low-dose SSRIs for the Overly Sensitive Esophagus...
November 1, 2012 - Clinical , Featured

By Sunhae Chang, PharmD Candidate c/o 2013 – When patients complain of heartburn, the blame usually shifts to gastroesophageal reflux disease (GERD).  Therefore, patients receive the “standard therapies for GERD”: antacids, histamine-2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), or prokinetics.1,2  Luckily, most patients respond well to these agents.1,2  Unfortunately, the not-as-lucky ones, despite PPI…

Duloxetine’s Effect on Blood Glucose Levels...
October 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief – Duloxetine is a serotonin (5HT) and norepinephrine (NE) reuptake inhibitor (SNRI) introduced to the US market in 2004, indicated for the treatment of diabetic neuropathic pain.1 A chemical figure of duloxetine is shown [in the PDF].2 It was developed in an effort to mimic tricyclic antidepressant mitigation of neuropathic pain…

The Role of NMDA in Electroconvulsive Therapy and Other...
October 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief – Electroconvulsive therapy (ECT) is a last-line procedure in the treatment of refractory depression, among other neuropsychological disorders.1 By inducing a seizure, neurotransmitters are released and the disease state may feature a modest mitigation in symptoms.1 Seizure medications such as benzodiazepines and barbiturates are prescribed to increase or heighten the seizure…

Medications Causing Body Temperature Fluctuations...
October 1, 2012 - Clinical , Featured

By: Elsa Thomas, Pharm.D. c/o 2013 – Human body uses various complex mechanisms to maintain its body temperature within a narrow range despite extreme environmental temperature changes as well as physiological changes. Several factors can affect body temperature such as disease states, growth, exercise, hormonal changes, and medications. Hypothermia can occurs as a result of…

Influenza Vaccines: Projected Strains for the 2012—20...
September 1, 2012 - Clinical , Featured

By: Joo Hee Kwon, Pharm.D. Candidate c/o 2013 – There are 3 antigenic types of influenza: A, B, and C. Influenza C causes mild illness and therefore does not cause epidemics.  In contrast, influenza A and B are capable of causing mild to severe flu and in some cases death.  An epidemic can occur depending…

Bisphosphonates and Atypical Fracture Risk...
September 1, 2012 - Clinical , Featured

By: Steve Soman, Pharm.D. Candidate c/o 2013 – Bisphosphonates are proven to enhance bone density and reduce fracture incidence in post-menopausal women but recent data suggests they may have adverse effects with regards to bone quality.  The drugs in this class can be differentiated as non-nitrogen containing (older generation) and nitrogen containing (newer generation) medications.…

Antiplatelet Use Following Acute Coronary Syndromes...
September 1, 2012 - Clinical , Featured

By: Addolorata Ciccone, Co-Copy Editor – Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction of coronary arteries.  ACS is stratified into three types, based on electrocardiogram (EKG) changes and the presence of cardiac biomarkers (e.g. troponin, creatinine phosphokinase, and myoglobin).  To guide treatment plans, it is important to identify…

Brand Vs. Generic: What Every Prescriber Should Know...
September 1, 2012 - Clinical , Featured , Professional Advice / Opinions

By: Marina Yermolayeva, PharmD Candidate c/o 2013 – “I’m allergic to the generic; I need the brand name medication,” is a common claim heard by many health care providers.  Managed care organizations get numerous calls from doctors and patients requesting prior authorizations to approve brand name medications whilst there are generic alternatives available on formulary.…

Quick Update: Triptan Pharmacology...
August 1, 2012 - Clinical

By: Neal Shah, Co-Editor-In-Chief – Migraines can be “classic” or “common.”  While all migraines feature unilateral, pulsating headaches, classic migraines feature an “aura” upon onset (whereas common migraines do not).  Pharmacologic treatment of migraines generally includes serotonin agonists (triptans).1 Triptans are selective agonists of the 5-hydroxytryptamine 1B and 1D (5HT1B/1D) subtypes.  By activating these receptors,…

Indications for Dialysis: A Mnemonic And Explanation...
August 1, 2012 - Clinical , Featured

By: Neal Shah, Co-Editor-in-Chief –  Dialysis is the removal of substances from intravascular circulation by filtration.1  Typically, dialysis is ordered when kidney function declines to 10–15% of normal function.2  The National Kidney Foundation’s Kidney Disease Outcome Quality Initiative (K/DOQI) recommends that planning for dialysis begin when patients reach chronic kidney disease stage 4, which is…

Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)...
August 1, 2012 - Clinical , Featured , In the News / Politics

By: Steve P. Soman – Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily oral drug.   First in its class, it is a selective β(3)-adrenoceptor agonist that improves symptoms associated with over active bladder (OAB) such as urinary incontinence, urgency, and urinary frequency by enhancing storage function and relaxing…

Post navigation

← Older posts
Newer posts →


Do You Want to be a Published Author? Submit your Article(s) Today!



Tweets by @RhoChiPost

HOME: Home Page

VOLUMES / ISSUES: 15 . 14 . 13 . 12 . 11 . 10 . 9 . 8 . 7 . 6 . 5 . 4 . 3 . 2 . 1

ARTICLES: Featured . In the News / Politics . Events . Clinical . Advice / Opinions . Puzzles

FOR AUTHORS: Guidelines . AMA Citation Generator . Sign Up . Suggest . Submit . Cite

ABOUT US: About the Rho Chi Post . The Editorial Team . Apply for a Position

SUBSCRIBE: Google Groups Email List


Copyright © 2011-2026 Rho Chi Post